NICE technology appraisal guidance
Issued: June 2012
TA259

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta259

1 Guidance

1.1 Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer in adults, only if:

  • their disease has progressed on or after one docetaxel-containing chemotherapy regimen, and

  • the manufacturer provides abiraterone with the discount agreed in the patient access scheme.

1.2 People currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the criteria in 1.1 should be able to continue therapy until they and their clinician consider it appropriate to stop.